Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06351345 · ClinicalTrials.gov registry record · Phase 2
129 Xenon Imaging in Patients Treated With Sotatercept
A Phase 2 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Bastiaan Driehuys.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT06351345: Recruiting Phase 2 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Bastiaan Driehuys.
NCT06351345 is a Phase 2 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension that is actively recruiting participants, run by Bastiaan Driehuys. The registered enrollment target is 14 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06351345, a Phase 2 study of Pulmonary Hypertension and Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Bastiaan Driehuys.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).
Conditions Studied
Interventions
- DRUG 129Xe Hyperpolarized
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2030-02-04 |
| Phase | Phase 2 |
What NCT06351345 shows while recruiting
NCT06351345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which 129Xe Hyperpolarized is the first listed.
NCT06351345 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06351345 about?
NCT06351345 is a clinical study titled "129 Xenon Imaging in Patients Treated With Sotatercept". Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).
What is the current status of trial NCT06351345?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2025-10-27. Estimated completion is 2030-02-04.
What conditions does trial NCT06351345 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT06351345?
The interventions under investigation include: 129Xe Hyperpolarized (DRUG).
Who is sponsoring clinical trial NCT06351345?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06351345 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06351345's enrollment target sits among peer trials
14 65th of 72 higher than 8 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy